Clinical Gastroenterology Vol.23 No.12(3-3)

Theme Present Status of Chemoprevention for Tumors Derived from Digestive Diseases
Title Chemoprevention of Gastric Cancer with Selective COX-2 Inhibitor : A New Option
Publish Date 2008/11
Author Hirohito Magari Department of Gastroenterology, Faculty of Medicine, Wakayama Medical University
Author Kimihiko Yanaoka Department of Gastroenterology, Faculty of Medicine, Wakayama Medical University
Author Hisanobu Deguchi Department of Gastroenterology, Faculty of Medicine, Wakayama Medical University
Author Mikitaka Iguchi Department of Gastroenterology, Faculty of Medicine, Wakayama Medical University
Author Masashi Oka Department of Gastroenterology, Faculty of Medicine, Wakayama Medical University
Author Masao Ichinose Department of Gastroenterology, Faculty of Medicine, Wakayama Medical University
[ Summary ] Stomach cancer is still the second leading cause of cancer-related deaths in our country. However, recent changes in environmental factors together with the progress in cancer therapies and diagnostic technologies have improved outlook. Nation-wide strategies for cancer screening and other forms of cancer check-ups have lead to decreases in both prevalence rates and death rates. It is obvious that Helicobacter pylori infection is a major factor involved in the stomach carcinogenesis. However, the risk of stomach cancer continues in some populations even after eradication therapy. Therefore, it is imperative that we develop strategies for the control of stomach cancer other than eradication. We must also anticipate the effects of chemoprevention for stomach cancer, employing NSAIDs. Previous epidemiologic studies and animal experiments have shown that NSAIDs, such as aspirin, inhibit carcinogenesis in the stomach. Some anti-tumorigenesis mechanisms are reported to function in relation to NSAIDs mainly to decrease the production of prostaglandin following the inhibition of COX-2 expression and then to induce apoptosis.
back